Terumo and WuXi Biologics Enter into Agreement on a Drug Product Plant in Leverkusen, Germany

Expanding production capacity and global responsiveness of Terumo’s CDMO business

TOKYO, JAPAN – May 14, 2025 – Terumo Corporation (TSE: 4543) today announced that it has reached an agreement with WuXi Biologics for Terumo to acquire WuXi Biologics’ drug product (DP) plant located in Leverkusen, Germany for 150 million Euro (about 24.6 billion yen*1).

Terumo develops containers such as prefilled syringes and drug delivery devices using materials suitable for pharmaceuticals. The company also engages in the CDMO*2 business for combination products of pharmaceuticals and medical devices, leveraging advanced manufacturing technologies. Terumo positions the globalization of the CDMO business as one of its future growth strategies.

Terumo aims to expand production capacity and strengthen its global responsiveness by utilizing the newly acquired DP plant as its first overseas CDMO production base. This will accelerate the global expansion of the CDMO business.

The DP plant acquired from WuXi Biologics is equipped with state-of-the-art facilities compliant with GMP*3 standards. It is also staffed with highly skilled personnel, production know-how, and a proven track record. Leveraging these assets, Terumo will commence the development and production of prefilled syringe products and vial products at the plant. This will enable the company to address the growing demand for CDMO services, particularly in Europe and the United States, driven by the rapid growth of biopharmaceuticals.

Currently, Terumo has CDMO production bases at the Kofu, Fujinomiya, and Yamaguchi factories. The company has continuously enhanced its production capacity in line with the expansion of the CDMO business. In December 2023, Terumo expanded the CDMO production capabilities by expanding the production lines at the Yamaguchi factory. Additionally, the company is in the process of installing new production lines in the Kofu factory’s newly constructed building, which is currently under construction and scheduled for completion in fiscal 2025. By establishing a new CDMO production base in Europe, Terumo aims to strengthen its global operations to meet the growing needs of pharmaceutical companies both domestically and internationally.

"The acquisition of the drug product plant is a pivotal step in enhancing the competitiveness of our CDMO business, and we are thrilled to have reached an agreement with WuXi Biologics,” said Hikaru Samejima, Chief Executive Officer, Terumo Corporation. “By integrating the high-quality and stable production operations of the Leverkusen plant and the exceptional talent supporting it with Terumo, we are confident that we will significantly elevate the global responsiveness of our CDMO business."

Overview of the drug product plant to be acquired from WuXi Biologics
Location                              Leverkusen, North Rhine-Westphalia, Germany
Site area of the plant        13,000㎡
Description of business   CDMO business for vial products (as of May 2025)
Number of employees      Approximately 150